Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAUTIFUL: Ivabradine in stable CAD and LVSD
NCT00143507Phase 3Completed
- Sponsor
- Servier
- Start
- Dec 2004
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary artery disease (CAD) and left ventricular systolic dysfunction (LVSD) comparing Ivabradine with Placebo (2 arms). Primary endpoint: Composite of Cardiovascular Death, Hospitalization for Acute Myocardial Infarction, or Hospitalization for New Onset or Worsening Heart Failure at 3 years. Started Dec 2004; status: completed.
02
Drugs
ivabradine
03
Conditions
coronary artery disease (CAD)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NCT00143507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143507.